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AbstrACt
Objectives This paper aims to investigate resident, facility 
and country characteristics associated with length of stay 
in long- term care facilities (LTCFs) across six European 
countries.
setting Data from a cross- sectional study of deceased 
residents, conducted in LTCFs in Belgium, England, 
Finland, Italy, the Netherlands and Poland.
Participants All residents aged 65 years and older at 
admission who died in a 3- month period residing in a 
proportional random sample of LTCFs were included.
Primary and secondary outcome measures The 
primary outcome was length of stay in days, calculated 
from date of admission and date of death. Resident, facility 
and country characteristics were included in a proportional 
hazards model.
results The proportion of deaths within 1 year of 
admission was 42% (range 32%–63%). Older age at 
admission (HR 1.04, 95% CI 1.03 to 1.06), being married/
in a civil partnership at time of death (HR 1.47, 95% CI 
1.13 to 1.89), having cancer at time of death (HR 1.60, 
95% CI 1.22 to 2.10) and admission from a hospital (HR 
1.84, 95% CI 1.43 to 2.37) or another LTCF (HR 1.81, 95% 
CI 1.37 to 2.40) were associated with shorter lengths of 
stay across all countries. Being female (HR 0.72, 95% CI 
0.57 to 0.90) was associated with longer lengths of stay.
Conclusions Length of stay varied significantly between 
countries. Factors prior to LTCF admission, in particular the 
availability of resources that allow an older adult to remain 
living in the community, appear to influence length of stay. 
Further research is needed to explore the availability of 
long- term care in the community prior to admission and its 
influence on the trajectories of LTCF residents in Europe.
IntrOduCtIOn
As the population ages, the need for acces-
sible, appropriate long- term care provision 
will become a global priority. Despite being 
reported as the least preferred place of death, 
older adults with dementia and multiple, 
complex conditions often die in long- term 
care facilities (LTCFs), although the propor-
tion of deaths differs significantly between 
countries.1–5 In England and Wales, LTCFs 
are projected to become the most common 
place of death for older adults by 2040.6
Previous reviews of studies containing 
community- based samples of older adults 
have identified numerous factors predictive 
of future LTCF admission, with older adults 
with dementia more likely to be admitted to 
an LTCF than those without.7 8 Postadmis-
sion, the factors associated with shorter and 
longer length of stay in an LTCF have also 
been explored9–14; a systematic review of 
these factors identified shorter lengths of stay 
associated with older age, being male, having 
a cancer diagnosis, shortness of breath, 
receipt of oxygen therapy and residence in an 
LTCF providing nursing care.15 In particular, 
the review found stronger evidence for the 
association of poor physical functioning and 
shorter lengths of stay, compared with cogni-
tive functioning. The findings of the review 
were limited as no international studies using 
data comparable between countries were 
strengths and limitations of this study
 ► The study sample included a large, representative 
sample of residents in long- term care facilities 
(LTCFs) across six European countries.
 ► The cohort of residents was identified retrospective-
ly after death, meaning that there was no loss to 
follow- up at the end of the study.
 ► The study collected data on LTCF characteristics, 
including LTCF type and size.
 ► Health- related characteristics were measured either 
at death or in the last month/week of life, limiting the 
generalisability of the findings to resident character-
istics at LTCF admission.
 ► The study was limited to data collected from LTCF 
staff members, increasing the likelihood of recall 
bias.
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identified and few studies included characteristics related 
to the facility or used data collected at time points post-
admission. More recently, length of stay in nursing homes 
across seven countries has been examined using interna-
tionally comparable data from the Services and Health 
for Elderly in Long TERm care (SHELTER) study.16 The 
sample was restricted to nursing homes, was neither 
randomly sampled nor representative of each country, 
and the findings were not reported between countries.17
In this analysis, we have used data from the Palliative 
Care for Older People in care and nursing homes in 
Europe (PACE) study, a retrospective, cross- sectional 
study of deaths in LTCFs, conducted in six European 
countries, which aimed to explore quality of dying and 
end- of- life care.18 The PACE study collected data on 
nationally representative samples of deaths in multiple 
types of LTCFs, allowing comparison of length of stay 
between countries. This paper aims to compare length of 
stay between countries and to investigate the association 
of resident, facility and country level factors with length 
of stay from admission to death in LTCFs. In doing so, 
it will explore differences in the characteristics of LTCF 
residents with varying lengths of stay and identify hetero-
geneity in a relatively under researched population.
MethOds
study design and setting
The PACE study undertook a retrospective, cross- sectional 
study of deaths in LTCFs in Belgium, England, Finland, 
Italy, the Netherlands and Poland. LTCFs were defined 
as a collective institutional setting where care is provided 
for older adult residents who reside there, 24 hours a day, 
7 days a week, for an undefined period of time.19 The 
care provided includes onsite provision of personal assis-
tance with activities of daily living, nursing and medical 
care may be provided onsite or by nursing and medical 
professionals working from an organisation external to 
the setting.19
In each country, a proportional random sampling 
framework of LTCFs was developed using national lists 
of LTCFs. In Italy, no national list of LTCFs was avail-
able, therefore, a cluster of nursing homes interested 
in research was used.17 In England, LTCFs were also 
recruited from Enabling Research in Care Homes, a 
network of LTCFs with an interest in research participa-
tion.20 The methods used to recruit the LTCF and ethical 
approvals are discussed in the study protocol and primary 
outcomes publication.21 22
Patient and public involvement
In each country, feedback on questionnaires for rela-
tives was provided by three relatives recruited by the 
researchers. In England, a research partnership group 
including carers and volunteers provided feedback on 
questionnaires for relatives. Patient and public involve-
ment is discussed in detail in the study protocol.21
study population
LTCFs that consented to take part in the study were asked 
to provide data on the facility and on all resident deaths in 
a retrospective period between 2015 and 2016. Residents 
were included in the study if they had died in the facility, 
or after transfer to hospital, in the past 3 months. For each 
identified resident, structured questionnaires were sent 
to the administrative staff (response rate 95.7%), facility 
manager (94.7%) and a staff member who knew the resi-
dent (81.6%). Questionnaires were also sent to the resi-
dent’s physician and the resident’s relative, however, data 
from these questionnaires are not used in this analysis.
Independent variables
Factors identified in a systematic review as having strong, 
moderate or weak evidence of being related to length of 
stay were used to identify variables of interest collected 
in the PACE study.15 The construction of each variable is 
detailed in table 1.
Demographic data were collected on resident age, 
gender, marital status and source of admission. Data on 
diagnoses of cancer, severe pulmonary disease or severe 
diabetes were collected, as was the presence of pressure 
ulcers or history of a stroke. Shortness of breath, oxygen 
therapy, assistance with eating or drinking and enteral, 
parenteral or artificial administration of nutrition 
during the last week of life were also recorded. Severity 
of dementia was calculated using a combined score from 
the Global Dementia Scale (GDS)23 and Cognitive Perfor-
mance Scale (CPS).24
The general health of the resident during the last week 
of life was documented using a scale of 0–100, with 0 
representing worst health possible and 100 representing 
the best health possible. Physical functioning was deter-
mined using two validated questionnaires, the Bedford 
Alzheimer Nursing- Severity Scale (BANS- S)25 and the 
EuroQol 5 dimensional (EQ- 5D).26 The BANS- S collected 
data on seven items; ability to dress oneself, sleep cycle, 
speech, eating, mobility, muscle flexibility and eye contact 
in the last month of life. The EQ- 5D measured quality of 
life in the last week of life, including anxiety or depres-
sion, mobility, self- care, usual activities and pain in the 
last week of life.
Contact with health services were measured by the 
number of visits either received or made by a physi-
cian, visits to a hospital and admissions to an emergency 
department. Place of death was determined as the facility, 
hospice or palliative care unit, or a hospital.
Using the typology developed by Froggatt et al, LTCFs 
were categorised by the type of care offered.27 These 
were: type 1; a facility where onsite care is provided by 
physicians, nurses and care assistants (present in Italy, 
Netherlands, Poland); type 2: a facility where onsite care 
is provided by nurses and care assistants with medical 
provision provided by local, external primary care 
services (present in all countries); type 3: a facility where 
onsite care is provided by care assistants, and nursing with 
medical provision provided by local, external primary care 
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Table 1 Definition of variables used in the analysis
Variable name Variable definition
Age Resident age at the time of admission.
Gender Resident gender at the time of admission.
Marital status Marital status at the time of death, grouped into married/in civil partnership or in long- term 
relationship, or other (divorced, widowed, never married).
Source of admission Source of admission to the LTCF, grouped into three categories, community, hospital or another 
LTCF.
Cancer Diagnosis based on the question ‘which of the following conditions was the resident suffering 
from at the time of death?’Severe pulmonary disease
Severe diabetes
Pressure ulcers Whether the resident had decubitus during the last week of life.
Stroke Whether the resident suffered a stroke in the last month of life.
Shortness of breath Whether the resident experienced shortness of breath during the last week of life, classed as not 
at all, somewhat or a lot.
Oxygen therapy Whether the resident received oxygen therapy in the last week of life.
Assistance with eating or 
drinking
Whether the resident received assistance with eating or drinking in the last week of life.
Enteral, parenteral or artificial 
administration of nutrition
Whether the resident received enteral,parenteral or artificial administration of nutrition in the last 
week of life.
Severity of dementia Very severe or advanced dementia was classed as a GDS score of 7 and a CPS score of 5 or 6. 
Severe dementia was classed as a GDS score less than 7 and a CPS score of 5 or 6, or a GDS 
score of seven and a CPS score of less than 5. Mild or moderate dementia was classed as a 
GDS score less than 7 and a CPS score of less than 5.
General health The general health of the resident during the last week of life, documented using a scale of 0 to 
100, with 0 representing worst health possible and 100 representing the best health possible.
Physical functioning Scores for each BANS- S item ranged from one to four, with one indicating ability and four 
indicating dependency, which were grouped into no or mild impairments (scores 1–2) versus 
moderate to severe impairments (scores 3–4).
Scores for each EQ- 5D item ranged from 0 to 5, with 0 indicating no problems or independence 
and 5 indicating severe problems or total dependence. These were grouped into no or mild 
impairments (scores 1–3) versus moderate to severe impairments (scores 4–5).
Physician visits The no of visits either received or made by a physician during the last month of life.
Hospital visits The no of visits to a hospital, geriatric ward, intensive care unit or general ward (for more than 
24 hours) during the last month of life.
Emergency department 
admissions
The no of admissions to a hospital emergency room (for less than 24 hours) during the last 
month of life.
Place of death Place of death was determined as the facility, a hospice or palliative care unit, or a hospital; 
including a general ward, intensive care unit or accident and emergency department.
LTCF type Each LTCF was categorised by the type of care offered. Type 1; a facility where onsite care is 
provided by physicians, nurses and care assistants (present in Italy, Netherlands, Poland); type 
2: a facility where onsite care is provided by nurses and care assistants with medical provision 
provided by local, external primary care services (present in all countries); type 3: a facility where 
onsite care is provided by care assistants, and nursing with medical provision provided by local, 
external primary care services (present in England).
LTCF funding status The funding status of the LTCF was either public (non- profit), private (non- profit) or private (for 
profit).
LTCF size The size of the facility was classed as either small or large, based on average bed number in 
each country sample.
BANS- S, Bedford Alzheimer Nursing- Severity Scale; CPS, Cognitive Performance Scale; EQ- 5D, EuroQol 5 dimensional; GDS, Global 
Dementia Scale; LTCF, long- term care facility.
 o
n
 M
arch 16, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-033881 on 8 March 2020. Downloaded from 
4 Collingridge Moore D, et al. BMJ Open 2020;10:e033881. doi:10.1136/bmjopen-2019-033881
Open access 
Figure 1 Recruitment to the PACE study and development 
of the dataset. LTCF, long- term care facility; PACE, Palliative 
Care for Older People in care and nursing homes in Europe.
services (present in England). The funding status of the 
LTCF was either public (non- profit), private non- profit or 
private for profit. The size of the facility was classed as 
either small or large, based on average bed number in 
each country sample.
dependent variable
Date of admission and date of death were used to calcu-
late length of stay in days in the facility.
data analysis
First, analysis was conducted by country on all LTCFs 
within the country sample, with LTCF type included 
as a factor if more than one type was present in the 
country. Second, analysis was restricted to residents in 
type 2 LTCFs, providing onsite nursing care and external 
medical provision, which are present in all six countries, 
allowing for comparison of similar LTCF types between 
countries.
The initial dataset contained data on 1707 participants, 
as detailed in figure 1. Participants were excluded if length 
of stay could not be calculated or was less than 1 day, if 
residents were younger than 65 years on admission, were 
missing data on age, or no questionnaire was returned by 
LTCF staff (n=470), resulting in a final sample of 1237 
participants. Analysis of LTCFs providing onsite nursing 
care only was conducted on 869 participants.
Univariate analysis of the variables was performed and 
significance tested using log rank tests and Kaplan- Meir 
curves were plotted for each factor. All factors associated 
with the outcome at a p≤0.2 at univariate analysis were 
entered into a proportional hazards model, including 
testing for potential interactions between age, gender 
and marital status. HRs, 95% CIs and p values that 
reached a statistical significance of p≤0.05 or p≤0.01 are 
reported. An HR above 1 indicates a greater risk of death, 
or a shorter length of stay, and an HR of less than 1 indi-
cates a lower risk of death or a longer length of stay. Multi-
collinearity was checked using variance inflation factors. 
Proportionality assumptions were tested by exploring 
time- dependant covariates and Schoenfeld residuals; 
and goodness of fit was tested using Cox- Snell residuals. 
A variable to identify each individual LTCF was added as 
a random, multilevel effect to account for multiple resi-
dents within the same LTCF. The final model used was a 
parametric proportional hazards model using a Weibull 
distribution. All analyses were performed using v16 
Stata.28
results
The characteristics of the sample are described in table 2. 
The non- response analysis did not identify significant 
differences in the lengths of stay of residents for whom a 
staff questionnaire was or was not completed and returned 
(p=0.356). The median length of stay was 73.4 weeks, 
ranging from 16 weeks in Poland to 103.9 weeks in 
Belgium. Average length of stay was 126 weeks (SD 157), 
ranging from 93 (SD 156) weeks in Poland to 163 (SD 
182) weeks in Belgium. The number of deaths within 
1 year of admission was 521 (42%), ranging from 85 
(32%) in Belgium to 165 (63%) in Poland. The mean age 
of residents at admission was 83.9 years (SD 7.2), ranging 
from 82.1 (SD 7.8) in Poland to 85.7 (SD 7.4) in England. 
The percentage of residents who were female was 67%, 
ranging from 64% in Belgium to 77% in England.
Analysis of all ltCFs by country
Table 3 shows the results of the proportional hazards 
model for each of the six countries, results that reached 
a statistical significance of p≤0.05 or p≤0.01 are indicated.
In Belgium, older age at admission (HR 1.05, 95% CI 
1.02 to 1.08), being married/in a civil partnership (HR 
2.65, 95% CI 1.68 to 4.16) and admission from hospital 
(HR 2.62, 95% CI 1.80 to 3.81) or another LTCF (HR 
2.14, 95% CI 1.25 to 3.67) were associated with shorter 
lengths of stay. Moderate or severe mobility problems 
(HR 0.34, 95% CI 0.14 to 0.86) were associated with 
longer lengths of stay.
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Table 4 Multilevel proportional hazards model—factors 
associated with length of stay in type 2 LTCFs across all six 
countries
HR 95% CI
Age at admission 1.04** 1.03 to 1.06
Being female 0.72** 0.57 to 0.90
Being married/in a civil 
partnership
1.47** 1.13 to 1.89
Source of admission—
community (ref)
  Hospital 1.84** 1.43 to 2.37
  Other LTCF 1.81** 1.37 to 2.40
Place of death—LTCF (ref)
  Hospice/PCU 1.15 0.75 to 1.78
  Hospital 1.30 0.81 to 2.07
General health 0.95 0.84 to 1.08
Cancer 1.60** 1.22 to 2.10
Severe pulmonary disease 1.19 0.89 to 1.61
EQ- 5D (moderate or severe 
problems)
  Anxiety or depression 1.10 0.87 to 1.37
  Pain 0.93 0.74 to 1.18
  Mobility 1.03 0.77 to 1.37
BANS- S (moderate or severe 
impairment)
  Speech 0.97 0.76 to 1.25
Dementia—resident did not 
have dementia (ref)
  Mild or moderate dementia 0.87 0.62 to 1.22
  Severe dementia 0.85 0.63 to 1.14
  Very severe or advanced 
dementia
0.78 0.57 to 1.05
Oxygen therapy 1.09 0.85 to 1.40
Hospital visits—none (ref)
  One or more 1.29 0.97 to 1.72
Emergency department admissions—none (ref)
  One or more 0.94 0.66 to 1.33
LTCF funding status—public—
non- profit (ref)
  Private—non- profit 1.28 0.95 to 1.74
  Private—profit 1.10 0.74 to 1.65
Country—Belgium (ref)
  Finland 1.42* 1.02 to 1.96
  Italy 1.93** 1.25 to 3.00
  Netherlands 1.24 0.83 to 1.84
  Poland 1.94** 1.27 to 2.96
  England 2.18** 1.21 to 3.93
All factors associated with the outcome at a p value of 0.2 at 
univariate analysis were entered into the multivariate model.
*P<0.05 **P<0.01.
BANS- S, Bedford Alzheimer Nursing- Severity Scale; EQ- 5D, 
EuroQol 5 dimensional; LTCF, long- term care facility; PCU, palliative 
care unit.
In England, older age at admission (HR 1.09, 95% 
CI 1.02 to 1.16), moderate or severe mobility problems 
(HR 19.95, 95% CI 1.62 to 245.72) and receipt of oxygen 
therapy (HR 9.69, 95% CI 1.55 to 60.61) were associated 
with shorter lengths of stay. Being female (HR 0.12, 95% 
CI 0.04 to 0.37), moderate or mild dementia (HR 0.23, 
95% CI 0.08 to 0.68), very severe or advanced dementia 
(HR 0.15, 95% CI 0.06 to 0.37), being somewhat short of 
breath (HR 0.15, 95% CI 0.05 to 0.46) and residing in a 
type 3 LTCF (HR 0.11, 95% CI 0.04 to 0.31) were associ-
ated with longer lengths of stay.
In Finland, the interactions between gender and being 
married/in a civil partnership (HR 6.45, 95% CI 1.21 
to 34.23) were associated with shorter lengths of stay. 
Moderate or severe impairment in ability to dress oneself 
(HR 0.12, 95% CI 0.02 to 0.74) was associated with longer 
lengths of stay.
In Italy, older age at admission (HR 1.04, 95% CI 1.01 
to 1.07) and having a cancer diagnosis (HR 1.85, 95% 
CI 1.12 to 3.06) were associated with shorter lengths of 
stay. Severe dementia (HR 0.56, 95% CI 0.32 to 0.99), 
moderate or severe impairment in ability to dress oneself 
(HR 0.32, 95% CI 0.12 to 0.90) and assistance with eating 
or drinking (HR 0.53, 95% CI 0.30 to 0.92) were associ-
ated with longer lengths of stay.
In Netherlands, older age at admission (HR 1.04, 95% 
CI 1.00 to 1.08), dying in hospital (HR 58.66, 95% CI 4.90 
to 702.44) and admission from hospital (HR 2.58, 95% CI 
1.31 to 5.08) or another LTCF (HR 2.73, 95% CI 1.37 to 
5.44) were associated with shorter lengths of stay.
In Poland, older age at admission (HR 1.07, 95% CI 
1.03 to 1.12), admission from hospital (HR 7.04, 95% CI 
3.11 to 15.94), one or more hospital visits (HR 2.18, 95% 
CI 1.01 to 4.72), moderate or severe eye contact impair-
ment (HR 2.17, 95% CI 1.19 to 3.96) and residing in a 
type 1 facility (HR 4.05, 95% CI 1.43 to 11.44) were asso-
ciated with shorter lengths of stay. Being female (HR 0.42, 
95% CI 0.21 to 0.86), moderate or severe mobility prob-
lems (HR 0.06, 95% CI 0.00 to 0.83) and residing in a 
not for profit facility (HR 0.22, 95%CI 0.10 to 0.49) were 
associated with longer lengths of stay.
Analysis of type 2 ltCFs across countries
Table 4 shows the results of the proportional hazards 
model for type 2 LTCFs across the six countries. Older 
age at admission (HR 1.04, 95% CI 1.03 to 1.06), being 
married/in a civil partnership (HR 1.47, 95% CI 1.13 
to 1.89), admission from a hospital (HR 1.84, 95% CI 
1.43 to 2.37) or another LTCF (HR 1.81, 95% CI 1.37 to 
2.40), having a cancer diagnosis (HR 1.60, 95% CI 1.22 
to 2.10) and residing in Italy (HR 1.93, 95% CI 1.25 to 
3.00), Poland (HR 1.94, 95% CI 1.27 to 2.96), England 
(HR 2.18, 95% CI 1.21 to 3.95) or Finland (1.42, 95% 
CI 1.02 to 1.96) compared with Belgium were associated 
with shorter lengths of stay. Being female (HR 0.72, 95% 
CI 0.57 to 0.90) was associated with longer lengths of 
stay.
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dIsCussIOn
summary of findings
In this study, we have examined the association between 
resident, facility and country- level factors with length 
of stay in an LTCF. The results show a large variation in 
length of stay between residents in the same country and 
between countries. The analysis identified four factors 
that are consistently statistically significant across all six 
countries and between countries; older age at admission, 
being admitted from a hospital or another LTCF, being 
married/in a civil partnership and being female.
strengths and limitations
This is the first study that the research team are aware 
of that compared length of stay until death in multiple 
types of LTCFs internationally. The data were collected 
across six European countries, using a standardised 
collection method within a representative, random, 
relatively large sample of LTCFs. It would be difficult to 
achieve a similar dataset in scope and size by combining 
nationally collected routine data, if such data were avail-
able. Previous epidemiological studies of different types 
of LTCFs have been restricted to nursing homes as one 
particular type of LTCF or facilities from one organisa-
tion17 29 30 potentially limiting the wider applicability of 
findings.
The main limitation of this analysis that the PACE 
study was developed to compare the outcomes, quality 
and costs of palliative and end- of- life care between coun-
tries.22 Consequently, much of the data collected were 
related to either the last month or week of life. Although 
the data were not collected to explore length of stay in 
LTCFs, they do allow for such an analysis. The majority 
of previous research in this area were prospective studies 
collecting data on explanatory variables at baseline and 
outcome data on death within a prespecified follow- up 
period.10–14 In both approaches, changes in the resident’s 
well- being during residence in the LTCF are potentially 
missed; however, this analysis is novel in its use of data 
collected at end of life rather than on LTCF admission. 
Future research would benefit from collecting data at 
multiple time points from LTCF admission to death to 
further explore how changes in resident health are asso-
ciated with length of stay.
The use of retrospective data is a common approach 
in palliative care research, with the last 3- month of life 
commonly used.31–35 The data used in this analysis were 
reported by LTCF staff, rather than retrieved from 
medical records, increasing the likelihood of measure-
ment error and recall bias.
Interpretation of findings
The findings indicate that length of stay in an LTCF is 
associated with pre- existing factors prior to admission. All 
four characteristics indicate that length of stay in an LTCF 
is influenced by factors prior to admission, in particular 
the availability of resources that allow an older adult to 
remain living in the community. Older adults with care 
needs in the community commonly receive care from 
spouses, where available.36 As women generally live longer 
than men, it is possible that partnerless older women are 
living in LTCFs longer than older, married men, due to 
lack of a spousal carer. The findings in Finland indicate 
that being married reduces the length of stay in women, 
however, this was not replicated in other countries. In 
addition to being more likely to enter an LTCF,37 this 
study indicates that partnerless, older women are also 
likely to live in an LTCF for longer
Admission to an LTCF often follows a period of hospi-
talisation or other enhanced care, where return to living 
in the community is no longer possible.38 In areas where 
integrated services for older people are well developed, 
emergency admission to a hospital is lower,39 supporting 
the idea that while older adults are remaining in the 
community for as long as possible before LTCF admis-
sion, their care needs may not necessarily be being met.
The relationship between physical functioning, cogni-
tive functioning and length of stay is less clear. In two 
countries, mobility problems were associated with longer 
lengths of stay, however, in England mobility problems 
were related to shorter lengths of stay. The relationship 
between poor mobility and longer lengths of stay could 
reflect a deterioration from admission to death; on admis-
sion, a resident may have few problems with mobility, 
subsequently declining over time, reflecting poor mobility 
before death in longer stay residents. It is less clear why 
residents with better mobility before death would have 
shorter lengths of stays. One diagnosis, cancer, was asso-
ciated with shorter lengths of stay in the between country 
analysis, possibly reflecting the relatively fast period of 
decline experienced in this condition.40
Dementia was related to longer lengths of stay in Italy 
and England. Although a diagnosis of dementia has been 
identified as the strongest predictor of care home admis-
sion,8 in this study, it has not been associated with shorter 
lengths of stay. The differences found here could be 
explained by the availability of other services; in England 
and Italy, it may be more difficult to live independently 
in the community with dementia; therefore, older adults 
may be admitted to an LTCF earlier, leading to a longer 
length of stay. Neither physical nor cognitive functioning 
was associated with shorter lengths of stay in the between 
country analysis, indicating that factors prior to admis-
sion have a greater influence on length of stay.
The findings also provide some evidence to indi-
cate that older adults use services which provide the 
minimum available care to meet their needs. In Poland 
and England, shorter lengths of stay were significantly 
associated with the highest level of care available (type 1 
and type 2, respectively). A possible explanation for this 
could be that admission criteria for facilities providing 
higher levels of care require residents to have greater 
health needs, resulting in shorter lengths of stay before 
death. Further research is needed to explore how the 
availability of different types of LTCF provision is utilised 
by the older adult population. In future, research 
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conducting international comparisons in this area may 
benefit from comparing countries with similar long- term 
care provision.
COnClusIOn
Older adults residing in LTCFs are a diverse population 
with multiple, often complex, healthcare needs. This 
study has highlighted the need for further research on 
the trajectories of older adults admitted to LTCFs, and 
their length of stay. In particular, further attention should 
be given to ensuring groups likely to have longer lengths 
of stay, namely partnerless older women, receive appro-
priate long- term care or other options to remain living in 
the community are available.
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